MAR 24, 2020 5:51 AM PDT

Ultra sensitive cancer diagnostic detects DNA "fingerprints" in liquid biopsies

WRITTEN BY: Tara Fernandes

Researchers from the Broad and Dana-Farber Cancer Institutes have developed a diagnostic technology that can be used to monitor patients for the presence of recurring cancer cells after receiving treatment. This “liquid biopsy” screening platform is so sensitive, that it can detect metastatic cancer cells years before they would show up using traditional techniques.

The retrospective study, published in Clinical Cancer Research, tracked banked blood samples from breast cancer patients in the years following their initial diagnosis and treatment. Nearly 30 percent of women diagnosed with breast cancer will develop metastatic disease, as a result of cancer cells breaking away from the original tumor in the breast and migrating to other parts of the body through the bloodstream or the lymphatic system.

Senior author Viktor Adalsteinsson and his team first used whole-exome DNA sequencing to identify the unique DNA “fingerprint” from the tumors isolated from each of the 142 patients in the study. Significantly, the researchers found trace amounts of these cancer DNA sequences in the patients’ blood samples up to three years before metastatic cancer recurrence was picked up using standard diagnostic approaches.

“By taking an individualized approach — searching for many mutations that are specific to one patient’s cancer — we could greatly increase our sensitivity to detect traces of cancer DNA in patients who had completed their initial treatment plan,” explained Adalsteinsson.

“And with that sensitivity, we could identify residual cancer from blood samples taken many months to years before a recurring case was diagnosed through standard approaches.”

Future studies are going to employ whole-genome sequencing to boost the test’s sensitivity by collecting more genetic information about the patient’s tumor. In whole-genome sequencing, large amounts of DNA are sequenced at a single time, allowing researchers to perform a more in-depth characterization of the patient’s entire genome. 

With this technology, cancer patients would be able to receive more timely interventions should their cancer return or residual malignant cells be present after their initial treatment.

According to Adalsteinsson, “When we did detect residual disease in blood, following initial courses of treatment, it was a strong predictor of future recurrence. While this was a retrospective study, if a blood biopsy can give clinicians this early warning in real-time, that might provide the opportunity to alter a patient’s outcome.”

 

 


Source: The Harvard Gazette, Clinical Cancer Research.

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
SEP 28, 2022
Health & Medicine
After COVID-19 Infection, Risk of Blood Clots Could Remain for a Year
SEP 28, 2022
After COVID-19 Infection, Risk of Blood Clots Could Remain for a Year
Blood clots are a known risk from a COVID-19 infection. Blood clots are clumps of blood that naturally form to help the ...
OCT 10, 2022
Neuroscience
Botox Can Relieve Depression & Anxiety, Now Researchers Know How
OCT 10, 2022
Botox Can Relieve Depression & Anxiety, Now Researchers Know How
Botox, or botulinum toxin, might be most popularly known as a treatment for wrinkles; it's a neurotoxic agent produced b ...
OCT 11, 2022
Clinical & Molecular DX
Researchers Discover Method of Synthesizing a Cancer Drug Discovered in the Australian Rainforest
OCT 11, 2022
Researchers Discover Method of Synthesizing a Cancer Drug Discovered in the Australian Rainforest
Tigilanol tiglate (also referred to as EBC-46) is a chemical compound with a storied history. Found naturally in the see ...
OCT 11, 2022
Cardiology
Refined Grain Consumption Increases Heart Disease Risk
OCT 11, 2022
Refined Grain Consumption Increases Heart Disease Risk
Refined grains like white bread have been linked to the development of premature coronary artery disease.
NOV 05, 2022
Health & Medicine
Autism Study Reveals Widespread Transcriptomic Changes in the Brain
NOV 05, 2022
Autism Study Reveals Widespread Transcriptomic Changes in the Brain
We know of some risk factors for autism spectrum disorder, and like other neuropsychiatric disorders, there is a genetic ...
NOV 22, 2022
Clinical & Molecular DX
Women With Benign Breast Diseases, Including Cysts and Fibroadenomas, Face Higher Risk of Breast Cancer
NOV 22, 2022
Women With Benign Breast Diseases, Including Cysts and Fibroadenomas, Face Higher Risk of Breast Cancer
Though they are very common, benign breast diseases may indicate an increased likelihood of developing breast cancer at ...
Loading Comments...